Amarin Corporation PLC is a Dublin-based pharmaceutical company dedicated to the development and commercialization of innovative therapies for cardiovascular diseases, primarily within the United States. The company is renowned for its flagship product, Vascepa, which has demonstrated significant efficacy in reducing triglyceride levels in patients at an elevated risk for cardiovascular events. With a robust commitment to enhancing cardiovascular health, Amarin is actively pursuing new clinical applications and market opportunities, thereby solidifying its position as a key player in the healthcare sector.
Click "Analyze" to generate stock analysis
AMRN Price Trend and Signals
AMRN Option Volumes & Open Interests (aggregated)
AMRN Put Call Ratios and IV (aggregated)
AMRN Financials
2025-10-24Neutralvolume_signal
Abnormal volume detected compared to 5-day moving average.
2025-10-24Neutralvolume_signal
Abnormal volume detected compared to 10-day moving average.
2025-10-24Neutralvolume_signal
Abnormal volume detected compared to 20-day moving average.
2025-10-24Neutralvolume_signal
Abnormal volume detected compared to 3 mon moving average.